Schwartsmann G - Search Results

1

In vivo inhibition of the pyrimidine de novo enzyme dihydroorotic acid dehydrogenase by brequinar sodium (DUP-785; NSC 368390) in mice and patients.

Peters GJ, Schwartsmann G, Nadal JC, Laurensse EJ, van Groeningen CJ, van der Vijgh WJ, Pinedo HM. Peters GJ, et al. Among authors: schwartsmann g. Cancer Res. 1990 Aug 1;50(15):4644-9. Cancer Res. 1990. PMID: 2164443

2

Mucocutaneous side effects of Brequinar sodium. A new inhibitor of pyrimidine de novo biosynthesis.

Schwartsmann G, Bork E, Vermorken JB, Nieboer C, Dodion P, ten Bokkel Huinink WW, Seldenrijk CA, Armand JP, Pinedo HM. Schwartsmann G, et al. Cancer. 1989 Jan 15;63(2):243-8. doi: 10.1002/1097-0142(19890115)63:2<243::aid-cncr2820630207>3.0.co;2-7. Cancer. 1989. PMID: 2521297 Clinical Trial.

3

Pharmacokinetics of Brequinar sodium (NSC 368390) in patients with solid tumors during a phase I study.

Schwartsmann G, van der Vijgh WJ, van Hennik MB, Klein I, Vermorken JB, Dodion P, ten Bokkel Huinink WW, Joggi G, Gall H, Crespeigne N, et al. Schwartsmann G, et al. Eur J Cancer Clin Oncol. 1989 Dec;25(12):1675-81. doi: 10.1016/0277-5379(89)90334-9. Eur J Cancer Clin Oncol. 1989. PMID: 2632251

4

DUP 785 (NSC 368390): schedule-dependency of growth-inhibitory and antipyrimidine effects.

Schwartsmann G, Peters GJ, Laurensse E, de Waal FC, Loonen AH, Leyva A, Pinedo HM. Schwartsmann G, et al. Biochem Pharmacol. 1988 Sep 1;37(17):3257-66. doi: 10.1016/0006-2952(88)90636-3. Biochem Pharmacol. 1988. PMID: 2840910

5

Phase I study of Brequinar sodium (NSC 368390) in patients with solid malignancies.

Schwartsmann G, Dodion P, Vermorken JB, ten Bokkel Huinink WW, Joggi J, Winograd B, Gall H, Simonetti G, van der Vijgh WJ, van Hennik MB, et al. Schwartsmann G, et al. Cancer Chemother Pharmacol. 1990;25(5):345-51. doi: 10.1007/BF00686235. Cancer Chemother Pharmacol. 1990. PMID: 2306795

6

The main steps in the development of anticancer agents.

Schwartsmann G, Winograd B, Pinedo HM. Schwartsmann G, et al. Radiother Oncol. 1988 Aug;12(4):301-13. doi: 10.1016/0167-8140(88)90020-5. Radiother Oncol. 1988. PMID: 3055073 Review.

7

Pharmacokinetics of Brequinar sodium (NSC 368390; DUP 785) in cerebrospinal fluid.

Schwartsmann G, van der Vijgh WJ, Klein I, van Groeningen CJ, Vermorken JB, Pinedo HM. Schwartsmann G, et al. Eur J Cancer Clin Oncol. 1988 Dec;24(12):1903-4. doi: 10.1016/0277-5379(88)90106-x. Eur J Cancer Clin Oncol. 1988. PMID: 3220087 No abstract available.

8

Clinical trials in advanced breast cancer.

Schwartsmann G, Pinedo HM. Schwartsmann G, et al. Eur J Cancer Clin Oncol. 1987 Jun;23(6):595-7. doi: 10.1016/0277-5379(87)90251-3. Eur J Cancer Clin Oncol. 1987. PMID: 3653182 No abstract available.

9

Resistance of HL-60 promyelocytic leukemia cells to induction of differentiation and its reversal by combination treatment.

Schwartsmann G, Pinedo HM, Leyva A. Schwartsmann G, et al. Eur J Cancer Clin Oncol. 1987 Jun;23(6):739-43. doi: 10.1016/0277-5379(87)90271-9. Eur J Cancer Clin Oncol. 1987. PMID: 2443360

10

A progress report of a phase I study of interferon-gamma and interleukin-2 and some comments on the mechanism of the toxicity due to interleukin-2.

Wagstaff J, Vermorken JB, Schwartsmann G, Scheper RJ, Hack CE, Nuijens JH, Eerenberg-Belmer AJ, Pinedo HM. Wagstaff J, et al. Among authors: schwartsmann g. Cancer Treat Rev. 1989 Jun;16 Suppl A:105-9. doi: 10.1016/0305-7372(89)90029-7. Cancer Treat Rev. 1989. PMID: 2504491 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

256 results

Search Page

Filters